Clinical Trials Download Patients Safety 
Cannabis Law Report
DECEMBER 9, 2021
The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec.
TheAnswerPage
JANUARY 11, 2022
Are you able to answer your patients’ medical marijuana questions? We also provide free downloadable resources: ‘The Endocannabinoid System and Medical Marijuana in 15 minutes!’ and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ Unfortunately, this did not occur.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
CannaMD
MARCH 8, 2021
If you’re a Florida medical marijuana patient, chances are you’ve heard of House Bill 1455 – a proposed bill making its rounds through the state legislature as we speak. But, behind the outrage, lies a larger conversation regarding free speech, fair pricing, and the sanctity of the physician-patient relationship.
Project CBD
FEBRUARY 28, 2023
Despite the companies’ submitting the required data demonstrating the “reasonable expectation of safety under the recommended conditions of use,” the FDA rejected the applications, citing the drug preclusion clause. Available at: www.fda.gov/media/131878/download. US Food and Drug Administration website. Accessed October 17, 2022.
Cannabis Law Report
JULY 15, 2022
“It’s very important from our perspective to ensure that the Australian patient gets medicine first. The first medicinal cannabis ‘mother’ plants are expected to be imported from Israel within a month, with manufacturing scheduled to begin within the first half of this year, to supply 5,000 Australian patients.
Cannabis Law Report
NOVEMBER 24, 2019
Do not offer CBD to manage chronic pain in adults unless as part of a clinical trial. After the 4-week trial, continue THC:CBD spray if the person has had at least a 20% reduction in spasticity-related symptoms on a 0 to 10 patient-reported numeric rating scale. the person’s clinical condition is stable.
Cannabis Law Report
NOVEMBER 24, 2021
However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. The review, however, did not cover patient access to medicinal cannabis. The states’ situation varies substantially.
Expert insights. Personalized for you.
52 
Let's personalize your content